Millennium Poised To Deliver Late-Stage Pipeline: Q&A With Dr. Karen Ferrante
This article was originally published in The Pink Sheet Daily
Executive Summary
Since its acquisition by Takeda in 2008, Millennium has been advancing its candidates and expanding its pipeline through deals, M&A and the assumption of internal Takeda oncology products. Near-term, it is expecting EU approval of ADCETRIS, licensed from Seattle Genetics, in the second half of 2012.